Global Respiratory Inhalers Patent Landscape Report 2025

Patent Landscape Report Coverage

The Global Respiratory Inhalers Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for respiratory inhalers include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within respiratory inhaler technologies.

Dry powder inhalers (DPIs) provide a user-friendly and environmentally friendly solution. DPIs are an essential part of contemporary respiratory therapy because of technological developments like smart inhalers with digital connectivity and better particle engineering, which increase drug delivery efficiency and patient adherence. Therefore, the development of such therapies has a significant impact on the patent landscape.

Global Respiratory Inhalers Patent Outlook

• The rising prevalence of respiratory disorders such as asthma and COPD is on the rise. This is leading to increased demand for efficient treatment options, like inhalers, to manage these chronic conditions.

• Major market players engaged in the patent landscape for respiratory inhalers include Pfizer & Co. Inc., Novartis Ag, Bayer Pharma Ag, and GSK Plc.

• The market is expanding due to rising awareness of respiratory health and improved access to healthcare facilities in developing nations. These elements increase the need for inhalers by facilitating earlier diagnosis and better treatment of respiratory disorders.

What are Respiratory Inhalers?

Respiratory inhalers are devices used to administer medication to the lungs. These devices are commonly used in treating chronic respiratory conditions such as asthma, COPD and others. The respiratory inhaler market continues to evolve, as the market is witnessing significant advancements with ongoing development and approval of new inhalers, thereby, expanding the available treatment options. Moreover, many patients find that inhalers are a more convenient and non-invasive way to administer drugs than injections. Hence, the use of cutting-edge inhaler treatments is encouraged by healthcare professionals and acts as a driving factor to boost market value in the forecast period.

Respiratory Inhalers Industry Growth Drivers

New Product Launches is Expected to Boost the Market Growth

The introduction of novel and cutting-edge respiratory inhalers propels market expansion by offering more convenient and efficient treatment choices. These developments improve patient adherence and outcomes by meeting the growing need for better respiratory disease management.

For instance, in April 2022, GlaxoSmithKline (GSK) launched its Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) as the first single-inhaler triple therapy (SITT) for patients with chronic obstructive pulmonary disease (COPD). It is advised to be taken once a day as per the company’s guidelines. These product launches have encouraged an increasing number of patent grants recorded from 1,065 patents in 2022 to 1,086 patents by 2023.

Rising Prevalence of Respiratory Diseases is Expected to Propel the Respiratory Inhalers Industry 

Inhalers are becoming more popular as more people seek efficient treatment for respiratory conditions like COPD and asthma. The market for respiratory inhalers is growing, driven by the rising incidence of respiratory diseases. This is driving ongoing innovation and new product development.

Global Respiratory Inhalers Patent Segmentation

The report provides an in-depth analysis of the patents in this field by the following segmentation -

Breakup by Product

• Dry Powder Inhalers

• Metered Dosed Inhalers

• Soft Mist Inhalers

• Nebulizers

Breakup by Category

• Conventional Inhalers

• Smart Inhalers

Breakup by Technology

• Manually Operated Inhaler Devices

• Digitally Operated Inhaler Devices

Respiratory Inhalers Patent Segmentation Analysis

The breakup based on category includes conventional inhalers and smart Inhalers. Advancements in inhaler technology, such as intelligent (smart) inhalers that track usage and issue alerts, improve patient compliance and treatment efficiency. These developments improve health outcomes and simplify disease management, increasing the appeal of inhalers to users.

The detailed technological data will be provided for all specified segments classified in this report.

Respiratory Inhalers Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for respiratory inhaler patents, having around 49,000 patents. The presence of a well-established healthcare infrastructure, a robust legal framework and prominent research institutions engaged in innovations contributes to the patent landscape significantly.

Holding a significant chunk of the global population, China is another vital jurisdiction and is witnessing rapid growth in patent filings. The expanding healthcare landscape in the region contributes to the evolving research capabilities, thereby influencing a surge in patent applications.

Patent Profile of Key Companies

Among the players with respiratory inhalers patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field.  Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

GSK PLC

It is a well-known international healthcare brand best known for its inventive line of respiratory inhalers, including the Ellipta model. The business is dedicated to creating cutting-edge inhaler technologies that will enhance the treatment of respiratory diseases like asthma and COPD.

F. Hoffmann La Roche

A multinational healthcare corporation with a focus on diagnostics and medications, Roche is well kn...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other companies include Pfizer & Co. Inc., Novartis Ag, and Bayer Pharma Ag, among others.

Reasons to Purchase this Report

The global respiratory inhalers patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by:

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and also makes it understandable which companies have important patents in this field of Respiratory Inhalers.

• Innovation Insights: The patent analysis reveals new innovations and technologies in the respiratory inhalers industry.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry.

• Risk Assessment: In technology-intensive fields such as pumps for microfluidic devices, risks of IP infringement are common. Analysing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

• Legal and Regulatory Compliance: Understanding the patent landscape is critical to ensuring compliance with patent laws and regulations. It helps stakeholders navigate license agreements, avoid infringement lawsuits, and effectively use IP assets in a global marketplace.

Key Questions Answered in the Global Respiratory Inhalers Patent Landscape Report 

• Who are the key players in the respiratory inhalers patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in respiratory inhalers patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the respiratory inhalers industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in respiratory inhalers?
• What are the challenges and opportunities in the respiratory inhalers patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in respiratory inhalers?

Related Reports

Global Upper Respiratory Tract Infection Treatment Market

Global Respiratory Gas Monitors Market

Global Bovine Respiratory Disease Treatment Market

Global Respiratory Care Device Market

Global Acute Respiratory Syndrome Treatment Market